📊 IMVT Key Takeaways
Is Immunovant, Inc. (IMVT) a Good Investment?
Immunovant exhibits strong revenue growth of 229% YoY but is deeply unprofitable with -$357.8M net income and severe cash burn of -$312.3M annually. While the company maintains a robust cash position of $994.5M with zero debt, current burn rates provide only 3-4 years of runway, creating existential pressure for profitability or dilutive financing.
Immunovant has a fortress balance sheet with nearly $1B in cash, negligible liabilities, and no debt, providing a multi‑year runway. However, fundamentals show minimal revenue, extremely negative margins, and heavy operating cash burn with no clear path to profitability yet. Wait for evidence of sustainable revenue and disciplined OpEx before reassessing.
Why Buy Immunovant, Inc. Stock? IMVT Key Strengths
- Strong cash position of $994.5M with zero debt provides multi-year operational runway
- Exceptional revenue growth of 229% YoY suggests meaningful market traction or recent commercialization milestone
- Excellent liquidity ratios (15.74x current and quick) ensure operational flexibility
- Robust cash position (~$995M) and zero debt
- Exceptional liquidity (current/quick ratio 15.7x)
- Triple‑digit YoY revenue growth off a small base
IMVT Stock Risks: Immunovant, Inc. Investment Risks
- Severe operating losses of -$354.7M with unsustainable net margin of -1434% indicating pre-profitability stage
- Annual cash burn of -$312.3M limits runway to approximately 3-4 years absent material revenue acceleration
- Minimal revenue base of $24.9M makes growth rate potentially unsustainable; company remains pre-commercial or early-stage
- Severe unprofitability with deeply negative operating and net margins
- High cash burn (FCF -$312M) implying future dilution risk when runway shortens
- Revenue base is small and potentially non‑recurring; no proven gross margin profile
Key Metrics to Watch
- Quarterly revenue growth rate and sustainability of 229% growth trajectory
- Monthly operating cash burn trend and path to break-even or profitability
- Cash balance trajectory and probability of requiring dilutive financing or capital raises
- Quarterly operating cash burn and cash runway (cash/OCF)
- R&D and SG&A trends vs. milestone progress; revenue recurrence/composition
Immunovant, Inc. (IMVT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 15.74x current ratio provides a solid financial cushion.
IMVT Profit Margin, ROE & Profitability Analysis
IMVT vs Healthcare Sector: How Immunovant, Inc. Compares
How Immunovant, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Immunovant, Inc. Stock Overvalued? IMVT Valuation Analysis 2026
Based on fundamental analysis, Immunovant, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Immunovant, Inc. Balance Sheet: IMVT Debt, Cash & Liquidity
IMVT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Immunovant, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.71 indicates the company is currently unprofitable.
IMVT Revenue Growth, EPS Growth & YoY Performance
Immunovant, Inc. Dividends, Buybacks & Capital Allocation
IMVT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Immunovant, Inc. (CIK: 0001764013)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 10, 2026 | 4 | xslF345X06/wk-form4_1775851530.xml | View → |
| Apr 10, 2026 | 4 | xslF345X06/wk-form4_1775851435.xml | View → |
| Apr 10, 2026 | 4 | xslF345X06/wk-form4_1775851354.xml | View → |
| Apr 9, 2026 | 4 | xslF345X06/wk-form4_1775766671.xml | View → |
| Apr 9, 2026 | 4 | xslF345X06/wk-form4_1775766526.xml | View → |
❓ Frequently Asked Questions about IMVT
What is the AI rating for IMVT?
Immunovant, Inc. (IMVT) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 66% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IMVT's key strengths?
Claude: Strong cash position of $994.5M with zero debt provides multi-year operational runway. Exceptional revenue growth of 229% YoY suggests meaningful market traction or recent commercialization milestone. ChatGPT: Robust cash position (~$995M) and zero debt. Exceptional liquidity (current/quick ratio 15.7x).
What are the risks of investing in IMVT?
Claude: Severe operating losses of -$354.7M with unsustainable net margin of -1434% indicating pre-profitability stage. Annual cash burn of -$312.3M limits runway to approximately 3-4 years absent material revenue acceleration. ChatGPT: Severe unprofitability with deeply negative operating and net margins. High cash burn (FCF -$312M) implying future dilution risk when runway shortens.
What is IMVT's revenue and growth?
Immunovant, Inc. reported revenue of $24.9M.
Does IMVT pay dividends?
Immunovant, Inc. does not currently pay dividends.
Where can I find IMVT SEC filings?
Official SEC filings for Immunovant, Inc. (CIK: 0001764013) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IMVT's EPS?
Immunovant, Inc. has a diluted EPS of $-2.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IMVT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Immunovant, Inc. has a SELL rating with 66% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IMVT stock overvalued or undervalued?
Valuation metrics for IMVT: ROE of -36.3% (sector avg: 15%), net margin of -1,434.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IMVT stock in 2026?
Our dual AI analysis gives Immunovant, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IMVT's free cash flow?
Immunovant, Inc.'s operating cash flow is $-312.3M, with capital expenditures of $0.0. FCF margin is -1,251.6%.
How does IMVT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,434.0% (avg: 12%), ROE -36.3% (avg: 15%), current ratio 15.74 (avg: 2).